Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by Sub-type: a report from the haematological malignancy research network. Br J Cancer. 2011;105(11):1684–1692. doi:10.1038/bjc.2011.450
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–4088. doi:10.1200/JCO.2005.12.051
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink A-M, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–942. doi:10.1016/S1470-2045(16)30051-1
   PubMed Web of Science ®Google Scholar
• Mato A, Jahnke J, Li P, et al. Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era. Haematologica. 2018;103(10):e462–e465. doi:10.3324/haematol.2017.185868
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528. doi:10.1056/NEJMoa1812836
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. doi:10.1056/NEJMoa1815281
   PubMed Web of Science ®Google Scholar
• Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evidence. 2022;1(7):1–13. doi:10.1056/EVIDoa2200006
   Google Scholar
• Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798. doi:10.1038/s41375-019-0602-x
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. doi:10.1016/S1470-2045(18)30788-5
   PubMed Web of Science ®Google Scholar
• Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363. doi:10.1002/ajh.25638
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. doi:10.1056/NEJMoa1509388
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Area Health Resources Files [Internet]. Health resources & services administration. 2022 [cited 2022 Oct 18]. https://data.hrsa.gov/topics/health-workforce/ahrf.
   Google Scholar
• CDC/ATSDR Social Vulnerability Index (SVI) [Internet]. Agency for toxic substances and disease registry. 2022 [cited 2022 Oct 18]. https://www.atsdr.cdc.gov/placeandhealth/svi/index.html.
   Google Scholar
• Kabadi SM, Goyal RK, Nagar SP, et al. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019;8(8):3803–3810. doi:10.1002/cam4.2268
   PubMed Web of Science ®Google Scholar
• Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050–1056. doi:10.1093/annonc/mdx031
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Medicare prescription drug benefit manual: chapter 6 – Part D drugs and formulary requirements (30.2.5 - protected classes). 2016 [cited 2024 Jan 15]. https://www.cms.gov/medicare/coverage/prescription-drug-coverage-contracting/prescription-drug-benefit-manual.
   Google Scholar
• Winkfield KM, Regnante JM, Miller-Sonet E, et al. Development of an actionable framework to address cancer care disparities in medically underserved populations in the United States: expert roundtable recommendations. J Clin Oncol Oncol Pract. 2021;17(3):e278–e293. doi:10.1200/OP.20.00630
   PubMedGoogle Scholar
• Walsh J, Harrison JD, Young JM, et al. What are the current barriers to effective cancer care coordination? A qualitative study. BMC Health Serv Res. 2010;10(1):132. doi:10.1186/1472-6963-10-132
   PubMedGoogle Scholar
• Bourgeois A, Horrill TC, Mollison A, et al. Barriers to cancer treatment and care for people experiencing structural vulnerability: a secondary analysis of ethnographic data. Int J Equity Health. 2023;22(1):58. doi:10.1186/s12939-023-01860-3
   PubMed Web of Science ®Google Scholar
• Onukwugha E, Osteen P, Jayasekera J, et al. Racial disparities in urologist visits among elderly men with prostate cancer: a cohort analysis of patient-related and county of residence-related factors. Cancer. 2014;120(21):3385–3392. doi:10.1002/cncr.28894
   PubMed Web of Science ®Google Scholar
• Jayasekera J, Onukwugha E, Cadham C, et al. An ecological approach to monitor geographic disparities in cancer outcomes. PLOS One. 2019;14(6):e0218712. doi:10.1371/journal.pone.0218712
   PubMed Web of Science ®Google Scholar
• Dreyer MS, Nattinger AB, McGinley EL, et al. Socioeconomic status and breast cancer treatment. Breast Cancer Res Treat. 2018;167(1):1–8. doi:10.1007/s10549-017-4490-3
   PubMed Web of Science ®Google Scholar
• Conti B, Bochaton A, Charreire H, et al. Influence of geographic access and socioeconomic characteristics on breast cancer outcomes: a systematic review. PLOS One. 2022;17(7):e0271319. doi:10.1371/journal.pone.0271319
   PubMed Web of Science ®Google Scholar
• Diaz A, Hyer JM, Barmash E, et al. County-level social vulnerability is associated with worse surgical outcomes especially among minority patients. Ann Surg. 2021;274(6):881–891. doi:10.1097/SLA.0000000000004691
   PubMed Web of Science ®Google Scholar
• Diaz A, Barmash E, Azap R, et al. Association of county-level social vulnerability with elective versus non-elective colorectal surgery. J Gastrointest Surg. 2021;25(3):786–794. doi:10.1007/s11605-020-04768-3
   PubMed Web of Science ®Google Scholar
• O'Connor JM, Sedghi T, Dhodapkar M, et al. Factors associated with cancer disparities among low-, medium-, and high-income US counties. JAMA Netw Open. 2018;1(6):e183146. doi:10.1001/jamanetworkopen.2018.3146
   PubMed Web of Science ®Google Scholar
• Michallet A-S, Campidelli A, Lequeu H, et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: a real-world experience of 71 patients treated in France: a study from the French innovative leukemia organization (FILO) group. Am J Hematol. 2017;92: E105–E107.
   PubMed Web of Science ®Google Scholar
• Eyre TA, Roeker LE, Fox CP, et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. Br J Haematol. 2020;188(6):918–923. doi:10.1111/bjh.16271
   PubMed Web of Science ®Google Scholar
• Azap RA, Hyer JM, Diaz A, et al. Association of county-level vulnerability, patient-level race/ethnicity, and receipt of surgery for early-stage hepatocellular carcinoma. JAMA Surg. 2021;156(2):197–199. doi:10.1001/jamasurg.2020.5554
   PubMed Web of Science ®Google Scholar
• Zyczynski T, Tabak Y, Sun X, et al. HSR22-184: the association of the social vulnerability index to timely treatment of metastatic cancers among insured adult patients in the US. JNCNN. 2022;20(3.5):HSR22-184. doi:10.6004/jnccn.2021.7232
   Google Scholar
• Grant SJ, Deal AM, Heiling HM, et al. A cross-sectional analysis of county-level social vulnerability and physical frailty among adults with hematological malignancies. Blood. 2021;138(Suppl 1):4130–4130. doi:10.1182/blood-2021-149742
   Google Scholar
• The French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage a): results of a randomized clinical trial on 612 patients. Blood. 1990;75:1414–1421.
   PubMed Web of Science ®Google Scholar
• CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91:861–868.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25)j:2745–2760. doi:10.1182/blood-2017-09806398
   PubMed Web of Science ®Google Scholar
• Avalon JC, Fuqua J, Miller T, et al. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with ibrutinib. Cardiooncology. 2021;7(1):38. doi:10.1186/s40959-021-00125-8
   PubMedGoogle Scholar
• Huang Q, Emond B, Lafeuille M-H, et al. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among medicare beneficiaries with chronic lymphocytic leukemia. Curr Med Res Opin. 2020;36:2009–2018.
   PubMed Web of Science ®Google Scholar